SDSha Du

Sha Du

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sha Du has a total of 30 co-authors. Here are the top co-authors by number of shared publications:

  • Chunrui Xie

    Institute of Cancer Stem Cell Dalian Medical University Cancer Center Dalian 116044 China

    3 shared publications
  • Songshu Meng

    Institute of Cancer Stem Cell, Dalian Medical University Cancer Center, Dalian, China

    3 shared publications
  • Dachuan Shen

    Department of Oncology Affiliated Zhongshan Hospital of Dalian University Dalian 116001 China

    2 shared publications
  • Kun Fang

    Central Laboratory, Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute Shenyang 110042, Liaoning, China

    2 shared publications
  • Lulu Hu

    Department of Laboratory Medicine Qingdao Central Hospital University of Health and Rehabilitation Sciences NO.369 Dengyun Road, Qingdao National High‐tech Industrial Development Zone Qingdao China

    2 shared publications
  • Ning Shen

    Institute of Cancer Stem Cell Dalian Medical University Cancer Center Dalian 116044 China

    2 shared publications

Latest Publications

  • FAM49B suppresses ovarian cancer cell growth through regulating MAPK signaling

    by Chen Yue, Dong Zhou, Yuzhao Zhou, Qidong Feng, Kun Fang, Songshu Meng, Weiting Yu, Sha Du, Dachuan Shen, Yifei Wang

    Recently, the family with sequence similarity 49 member B (FAM49B, also called CYRI-B) has garnered attention as a new target in cancer development. FAM49B is upregulated in ovarian cancer tissues; however, its role and mechanism in ovarian cancer progression remain unknown. Herein, we demonstrated that FAM49B knockdown significantly increases ovarian cancer cell viability, EdU incorporation, and clonogenic growth. In contrast, the forced expression of FAM49B achieved opposite effects. Furthermore, an ovo model was used to assess the in vitro effects of FAM49B depletion or overexpression on the growth of ovarian cancer. In a xenograft model, we observed that FAM49B overexpression alleviated tumor formation. Transcriptomic analysis of FAM49B-depleted and control cells revealed that FAM49B silencing upregulated the MAPK pathway. Consistent with the transcriptomic analysis results, we noted that FAM49B knockdown enhanced EGFR activation and downstream MEK-ERK signaling; in contrast, FAM49B overexpression exhibited opposite trends. In addition, FAM49B played a role in EGF-induced sphere growth of ovarian cancer cells. Notably, treatment with the MEK inhibitor trametinib considerably impaired the increased cell growth by FAM49B knockdown in cell culture and ovo models. Collectively, our results suggest that FAM49B can suppress the growth of ovarian cancer cells by regulating the MAPK signaling pathway.

  • Open Access

    Dietary Palmitic Acid Drives a Palmitoyltransferase ZDHHC15‐YAP Feedback Loop Promoting Tumor Metastasis

    by Jianxin Wang, Dachuan Shen, Jian Jiang, Lulu Hu, Kun Fang, Chunrui Xie, Ning Shen, Yuzhao Zhou, Yifei Wang, Sha Du, et al.

    Elevated uptake of saturated fatty acid palmitic acid (PA) is associated with tumor metastasis; however, the precise mechanisms remain partially understood, hindering the development of therapy for PA‐driven tumor metastasis. The Hippo–Yes‐associated protein (Hippo/YAP) pathway is implicated in cancer progression. Here it is shown that a high‐palm oil diet potentiates tumor metastasis in murine xenografts in part through YAP. It is found that the palmitoyltransferase ZDHHC15 is a YAP‐regulated gene that forms a feedback loop with YAP. Notably, PA drives the ZDHHC15‐YAP feedback loop, thus enforces YAP signaling, and hence promotes tumor metastasis in murine xenografts. In addition, it is shown that ZDHHC15 associates with Kidney and brain protein (KIBRA, also known as WW‐ and C2 domain‐containing protein 1, WWC1), an upstream component of Hippo signaling, and mediates its palmitoylation. KIBRA palmitoylation leads to its degradation and regulates its subcellular localization and activity toward the Hippo/YAP pathway. Moreover, PA enhances KIBRA palmitoylation and degradation. It is further shown that combinatorial targeting of YAP and fatty acid synthesis exhibits augmented effects against metastasis formation in mice fed with a Palm diet. Collectively, these findings uncover a ZDHHC15‐YAP feedback loop as a previously unrecognized mechanism underlying PA‐promoted tumor metastasis and support targeting YAP and fatty acid synthesis as potential therapeutic targets in PA‐driven tumor metastasis.


  • SPTLC2 drives an EGFR-FAK-HBEGF signaling axis to promote ovarian cancer progression

    by Xingyue Zhai, Ning Shen, Tao Guo, Jianxin Wang, Chunrui Xie, Yukai Cao, Ling Liu, Yumei Yan, Songshu Meng, Sha Du

    The epidermal growth factor receptor (EGFR) signaling pathway is frequently associated with ovarian cancer (OC) progression. However, inhibition of EGFR signaling in OC patients achieved limited therapeutic effects, highlighting the need to define the mechanism of EGFR deregulation in OC development. Herein we showed that serine palmitoyltransferase long chain base subunit 2 (SPTLC2) acts as a positive regulator in the EGFR signaling pathway in OC. Phenotypically, depletion of SPTLC2 suppressed clonogenic growth and migration of OC cells in vitro and in ovo, as well as metastasis in OC xenograft models, whereas overexpression of SPTLC2 yielded opposite effects. Mechanistically, SPTLC2 drives an EGFR-FAK-HBEGF signaling axis via binding with EGFR. Notably, the serine palmitoyltransferase activity of SPTLC2 is critical for regulation of the EGFR-FAK-HBEGF signaling axis and activity in OC progression. Clinically, high SPTLC2 expression is associated with high-grade serous ovarian cancer and metastasis. Collectively, our findings establish an oncogenic role of SPTLC2 in OC growth and progression though upregulation of EGFR signaling and suggest that SPTLC2 represents a potential therapeutic target in EGFR-driven ovarian cancer patients.


  • Open Access

    Osimertinib induces paraptosis and TRIP13 confers resistance in glioblastoma cells

    by Lulu Hu, Ji Shi, Dachuan Shen, Xingyue Zhai, Dapeng Liang, Jing Wang, Chunrui Xie, Zhiyu Xia, Jing Cui, Feng Liu, et al.

    The efficacy of osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, has been evaluated in glioblastoma (GBM) through preclinical and clinical trials. However, the underlying mechanism of osimertinib-induced GBM cell death and the underlying resistance mechanism to osimertinib remains unclear. Here, we demonstrate that Osimertinib induces paraptosis in GBM cells, as evidenced by the formation of cytoplasmic vacuoles, accumulation of ubiquitinated proteins, and upregulation of endoplasmic reticulum (ER) stress markers like CHOP. Additionally, neither apoptosis nor autophagy was involved in the osimertinib-induced cell death. RNAseq analysis revealed ER stress was the most significantly downregulated pathway upon exposure to osimertinib. Consistently, pharmacologically targeting the PERK-eIF2α axis impaired osimertinib-induced paraptosis. Notably, we show that the expression of thyroid receptor-interacting protein 13 (TRIP13), an AAA+ATPase, alleviated osimertinib-triggered paraptosis, thus conferring resistance. Intriguingly, MK-2206, an AKT inhibitor, downregulated TRIP13 levels and synergized with Osimertinib to suppress TRIP13-induced high GBM cell growth in vitro and in vivo. Together, our findings reveal a novel mechanism of action associated with the anti-GBM effects of osimertinib involving ER stress-regulated paraptosis. Furthermore, we identify a TRIP13-driven resistance mechanism against Osimertinib in GBM and offer a combination strategy using MK-2206 to overcome such resistance.